Search

Your search keyword '"A. Juan-Mas"' showing total 36 results
Start Over Author "A. Juan-Mas" Search Limiters Peer Reviewed
36 results on '"A. Juan-Mas"'

1. Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes

Author

Aterido, Adrià, López-Lasanta, María, Blanco, Francisco, Juan-Mas, Antonio, García-Vivar, María Luz, Erra, Alba, Pérez-García, Carolina, Sánchez-Fernández, Simón Ángel, Sanmartí, Raimon, Fernández-Nebro, Antonio, Alperi-López, Mercedes, Tornero, Jesús, Ortiz, Ana María, Fernández-Cid, Carlos Marras, Palau, Núria, Pan, Wenjing, Byrne-Steele, Miranda, Starenki, Dmytro, Weber, Daniel, Rodriguez-Nunez, Ivan, Han, Jian, Myers, Richard M., Marsal, Sara, and Julià, Antonio

Published
2024
Full Text
View/download PDF

2. Osseous sarcoidosis presenting as lytic and blastic bone lesions: A rare diagnostic challenge

Author

J. Bastidas, L. López-Nuñez, R. Faré, Javier G. Moríñigo, I. Ros, and A. Juan Mas

Subjects
Sarcoidosis, Osseous bone lesions, Granuloma, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Osseous sarcoidosis is a rare manifestation of sarcoidosis, often mimicking other conditions like metastatic disease. Skeletal involvement occurs in only 3%-13% of cases (1), making diagnosis challenging. We present the case of a 63-year-old female with a 1-month history of inflammatory bone pain and multiple lytic and blastic lesions.A 63-year-old female presented with a 1-month history of inflammatory pain in the left hip and lumbar spine. Radiological studies, including magnetic resonance imaging (MRI) and computed tomography (CT), revealed multiple bone lesions throughout the lumbar spine, sacrum and iliac bones, raising suspicion of metastatic disease a bone biopsy confirmed a diagnosis of sarcoidosis.MRI and CT showed lytic and blastic lesions in the axial skeleton, with FDG-PET indicating diffuse uptake in the iliac bone and mediastinal adenopathy. Imaging was crucial in ruling out metastases and guiding the biopsy, which confirmed the diagnosis.Osseous sarcoidosis is a rare entity that poses a significant diagnostic challenge, often resembling metastatic disease. Imaging techniques such as MRI and CT, combined with biopsy, are effective, noninvasive methods for evaluation and diagnosis. The patient was treated with corticosteroids in high doses and systemic methotrexate, showing improvement in inflammatory pain and stabilization of the bone lesions.

Published
2025
Full Text
View/download PDF

3. Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry

Author

Juan Molina-Collada, Marta Domínguez-Álvaro, Rafael B. Melero-González, Eugenio de Miguel, Maite Silva-Díaz, Jesús Alejandro Valero Jaimes, Ismael González, Julio Sánchez Martín, Javier Narváez, Joan Calvet, Ivette Casafont-Solé, Jose A Román Ivorra, Selene Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María Sagrario Bustabad Reyes, Cristina Campos Fernández, María Alcalde Villar, Antonio Juan Mas, Ricardo Blanco, and on behalf of the ARTESER Project Collaborative Group

Subjects
Mortality, Survival, Giant cell arteritis, Vasculitis, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Objectives To compare mortality rates between GCA patients and the general population in Spain, and to identify associated factors influencing mortality. Methods ARTESER, a multicenter registry by the Spanish Society of Rheumatology, includes GCA patients from June 2013 to March 2019. Demographic, clinical, imaging, histological and mortality data were collected retrospectively. Only patients with at least one year of follow-up were included for analysis. The mortality rates were expressed as the number of deaths per 1000 person-years, with 95% confidence interval (CI) by sex and age group. Kaplan-Meier method was performed for survival analysis. The factors influencing mortality were analyzed using Cox regression model. Results A total of 1200 patients with GCA were analyzed, with a mean (SD) follow-up of 2.18 (1.53) years. The overall five-year cumulative mortality rate (95%CI) was 37.86 (31.75-43.96) per 1000 patients/year. The cumulative mortality rate was significantly higher in males than females (59.04vs29.06; p

Published
2025
Full Text
View/download PDF

4. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry

Author

Tatiana Cobo-Ibáñez, Ivan Castellví, Ana Pros, Marta Domínguez-Álvaro, Laura Nuño-Nuño, Julia Martínez-Barrio, Vega Jovaní, Fredeswinda Romero-Bueno, Esther Ruiz-Lucea, Eva Tomero, Ernesto Trallero-Araguás, Javier Narváez, Jordi Camins-Fàbregas, Alberto Ruiz-Román, Jesús Loarce-Martos, Susana Holgado-Pérez, V Miguel Flores-Rodríguez, Francisca Sivera, Carolina Merino-Argumanez, Antonio Juan-Mas, Irene Altabás-González, María Martín-López, Joaquín María Belzunegui-Otano, Carmen Carrasco-Cubero, Mercedes Freire-González, Iñigo Rúa-Figueroa, Nuria Lozano-Rivas, Julio David Suarez-Cuba, Olga Martínez, Rafaela Ortega-Castro, Patricia Alcocer, Alejandro Gómez-Gómez, Olga Sánchez-Pernaute, José Luis Tandaipan, Irene Carrión-Barberà, Chamaida Plasencia-Rodríguez, Oihane Ibarguengoitia-Barrena, Paola Vidal-Montal, Vera Ortiz-Santamaria, Noemi Garrido-Puñal, Anne Riveros, Esmeralda Delgado-Frías, Juan Miguel López-Gómez, Carmen Barbadillo, José María Pego-Reigosa, Beatriz E. Joven-Ibáñez, Jesús Alejandro Valero-Jaimes, Elena Naveda, Ana Isabel Turrión-Nieves, Daniel Seoane-Mato, Francisco Javier Prado-Galbarro, and M Ángeles Puche-Larrubia

Subjects
Idiopathic inflammatory myopathies, Antisynthetase, Autoantibodies, Activity, Damage, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Objective To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Methods Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. Results A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p

Published
2025
Full Text
View/download PDF

5. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

Author

Jesús Tornero, Alba Erra, Santos Castañeda, Carolina Pérez-García, Raimon Sanmartí, Sara Marsal, Ingrid Moller, Esperanza Naredo, Miguel A González-Gay, Celia Erausquin, Ivan Castellví, Javier Llorca, Alejandro Muñoz, María Galindo, Enrique Raya, Lydia Abasolo, Gema Bonilla, Alfonso Corrales, Inmaculada Ureña, Carlos Rodríguez-Lozano, Carlos González-Juanatey, Cristina Fernandez Carballido, Francisco J López-Longo, Miguel Ángel González-Gay, Eduardo Collantes, José A Miranda-Filloy, Sagrario Bustabad, Indalecio Monteagudo, Jose A Piqueras, Tatiana Cobo, Joan Maymó, Carmen Barbadillo, Soledad Ojeda, Jaime Calvo Alen, Antonio Fernandez Nebro, Isabel Rodríguez, Pilar Font, Martina Steiner, Eugenio Chamizo Carmona, Beatriz González Álvarez, Santiago Munoz, Joan M Nolla, Fernando Sánchez-Alonso, Julio Sanchez, Raul Menor Almagro, Ana Pérez Gómez, Monica Ibañez, Elena Heras-Recuero, Trinidad Pérez Sandoval, Miren Uriarte-Ecenarro, Angela Pecondón, Hye Sang Park, Jessica Polo y La Borda, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, José L FernándezSueiro, José A Pinto-Tasende, Eugenia Gonzálezde Rábago, María J González-Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol, Gabriela Ávila, Cayetano Alegre, Fernando Gamero, José García Torón, María P Moreno-Gil, Antonio Juan-Mas, Pilar Espiño, Inmaculada Ros, Horacio Berman, Oscar Fontseré Patón, Benjamín Fernández Gutiérrez, José M Pina-Salvador, María D Fábregas, Montserrat Romera, Jesús A García-Vadillo, Rosario García de Vicuña, María A Belmonte, María V Irigoyen, Olga Martínez González, Rebeca Belmonte Gómez, Pastora Granados Bautista, Azucena Hernández Sanz, José Santos Rey, Carmen O Sánchez-González, Javier Bachiller, Antonio Zea, Francisco J Manero, Chesús Beltrán Audera, Marta Medrano, Jesús Babío Herráez, Javier del Pino, Ruth López González, María Enriqueta Peiró, José M Senabre, José C Rosas, Isabel Rotés, Estefanía Moreno, Javier Calvo, Amalia Rueda, Pilar Morales, Ana Nieto, Ana Ruibal Escribano, Sergio Ros Expósito, Ginés Sánchez Nievas, Enrique Júdez Navarro, Manuela Sianes Fernández, Silvia Martínez Pardo, Manel Pujol, Alberto Cantabrana, Esmeralda Delgado, Sergio Rodríguez Montero, Javier Rivera Redondo, Teresa González Hernández, Francisco J González-Polo, José M Moreno, Emilio Giner Serret, Laura Cebrián Méndez, María Teresa Navío, Teresa Pedraz Penalva, Encarnación Pagán, Pablo Mesadel Castillo, Ana Cruz, Ana Turrión, Desireé Ruíz, Antonio López Meseguer, Manuel J Moreno, Luis F Linares, Mercedes Morcillo, María L González-Gómez, José M Aramburu, Natalia A Rivera, Olaia Fernández Berrizbeitia, Manel Riera, Yolanda María León, Miriam Amirall, Jordi Fiter, Julia Fernández Melón, Luis Espadaler, Joaquín Belzunegui, Inmaculada Bañegil, César Díaz, Ramón Valls, María Bonet, Eva Revuelta Evrard, Javier R Godo, and José A González-Fernández

Subjects
Medicine
Abstract

Objective To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients.Methods Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics at tertiary centres for 7.5 years, were retrospectively analysed to test the performance of the Systematic Coronary Risk Assessment (SCORE), the modified version (mSCORE) European Alliance of Rheumatology Associations (EULAR) 2015/2016, the SCORE2 algorithm (the updated and improved version of SCORE) and the QRESEARCH risk estimator version 3 (QRISK3).Results Over 4790 years of follow-up, there were 34 CV events, resulting in a linearised rate of 7.10 per 1000 person-years (95% CI 4.92 to 9.92). The four CV risk scales showed strong correlations and all showed significant associations with CV events (p

Published
2024
Full Text
View/download PDF

6. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study

Author

Cesar Díaz-Torné, Virginia Ruiz-Esquide, Clementina López-Medina, Alejandro Balsa, Alejandro Escudero-Contreras, Rafaela Ortega-Castro, Sara Manrique-Arija, Chamaida Plasencia-Rodríguez, Natalia Mena-Vazquez, Ana Martínez-Feito, Jerusalem Calvo-Gutiérrez, M Carmen Ábalos-Aguilera, Francisco Cepas, Regina Faré-García, Antoni Juan-Mas, Luis Sainz, Francisco Javier Godoy-Navarrete, Isabel Añón-Oñate, and Marina Soledad Moreno-García

Subjects
Medicine
Abstract

Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels.Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off:

Published
2024
Full Text
View/download PDF

7. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

Author

Santos Castañeda, Ricardo Blanco, Héctor Corominas, Patricia Carreira, Ivan Castellví, Eugenio De Miguel, Javier Narváez, Judit LLuch, Ivette Casafont-Solé, Jose María Pego, Lydia Abasolo, Carmen Larena, Francisco Ortiz-Sanjuán, Clara Moriano Morales, Elvira Díez Álvarez, Miguel Ángel González-Gay, Berta Magallares, Monica Ibañez Barcelo, Laura Garrido Courel, Vanesa Hernandez Hernandez, Patricia Moya Alvarado, Anne Riveros Frutos, Margarida Vasques Rocha, María Alcalde Villar, Antonio Juan Mas, Julio Sanchez, Joan Calvet, Clara Molina Almela, Amalia Rueda Cid, Cristina Campos Fernández, Carmen Riesco Bárcena, Patricia Moran Alvarez, Judit Font Urgelles, Alejandro Muñoz Jiménez, Delia Fernández-Lozano, Iñigo Hernández-Rodríguez, Marta Domínguez-Álvaro, Maite Silva-Díaz, Joaquín María Belzunegui, Eva Galíndez-Agirregoikoa, Vicente Aldaroso, Javier Loricera, Noemi Garrido-Puñal, Vanessa Andrea Navarro, Tarek Carlos Salman Monte, Trinidad Pérez Sandoval, Ismael González Fernández, Javier Mendizábal-Mateos, María Concepción Fito Manteca, Natividad del Val del Amo, Loreto Horcada Rubio, Inmaculada Paniagua Zudaire, Ricardo Gutiérrez Polo, Juliana Restrepo Vélez, Eduardo Loza Cortina, Elisa Fernández Fernández, Tomás Almorza, Leticia Léon Mateos, Luis Rodríguez Rodríguez, Pia Mercedes Lois Bermejo, Selene Labrada Arrabal, Susana Holgado Pérez, Jordi Camins, Javier Calvo Catalá, Rafael Benito Melero, Francisco Maceiras, Nair Pérez, Ceferino Barbazán, Irena Altabás, John Guzman, Paula Valentina Estrada Alarcón, Ana Milena Millán, AnaF Cruz Valenciano, Félix Cabero del Pozo, AnaBelén Rodríguez Cambrón, Cristina Macia Villa, Inmaculada Ros Vilamajó, Elide Toniolo, Ana Paula Cacheda, María Sagrario Bustabad Reyes, María García González, Alicia García Dorta, Jaime Calvo Allen, Miren Uriarte-Ecenarro, Cristina Valero Martínez, Esther F Vicente Rabaneda, Carlos García Porrúa, Carlota Laura Iñiguez Ubiaga, Noelia Álvarez Rivas, Tomás Ramón Vázquez Rodríguez, José Alberto Miranda Filloy, Amalia Sánchez-Andrade Fernández, Carlos Galisteo Lencastre Da Veiga, María Jesús García Villanueva, Marina Tortosa Cabañas, Marta Serrano Warleta, Aliuska Palomeque Vargas, Alberto Ruiz Román, Clara Aguilera Cros, JoséA Román Ivorra, Anderson Huaylla, Itziar Calvo Zorrilla, Jesús A Valero-Jaimes, Luis López Domínguez, Cesar Antonio Egues Dubuc, and Lucia Silva Fernández

Subjects
Medicine
Abstract

Objective This study aimed to estimate the incidence of giant cell arteritis (GCA) in Spain and to analyse its clinical manifestations, and distribution by age group, sex, geographical area and season.Methods We included all patients diagnosed with GCA between 1 June 2013 and 29 March 2019 at 26 hospitals of the National Health System. They had to be aged ≥50 years and have at least one positive results in an objective diagnostic test (biopsy or imaging techniques), meet 3/5 of the 1990 American College of Rheumatology classification criteria or have a clinical diagnosis based on the expert opinion of the physician in charge. We calculated incidence rate using Poisson regression and assessed the influence of age, sex, geographical area and season.Results We identified 1675 cases of GCA with a mean age at diagnosis of 76.9±8.3 years. The annual incidence was estimated at 7.42 (95% CI 6.57 to 8.27) cases of GCA per 100 000 people ≥50 years with a peak for patients aged 80–84 years (23.06 (95% CI 20.89 to 25.4)). The incidence was greater in women (10.06 (95% CI 8.7 to 11.5)) than in men (4.83 (95% CI 3.8 to 5.9)). No significant differences were found between geographical distribution and incidence throughout the year (p=0.125). The phenotypes at diagnosis were cranial in 1091 patients, extracranial in 337 patients and mixed in 170 patients.Conclusions This is the first study to estimate the incidence of GCA in Spain at a national level. We found a predominance among women and during the ninth decade of life with no clear variability according to geographical area or seasons of the year.

Published
2024
Full Text
View/download PDF

8. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

Author

Silva-Díaz, Maite, Blanco, Francisco J., Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez-Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Prado-Galbarro, Francisco Javier, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2022
Full Text
View/download PDF

9. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry.

Author

Cobo-Ibáñez, Tatiana, Castellví, Ivan, Pros, Ana, Domínguez-Álvaro, Marta, Nuño-Nuño, Laura, Martínez-Barrio, Julia, Jovaní, Vega, Romero-Bueno, Fredeswinda, Ruiz-Lucea, Esther, Tomero, Eva, Trallero-Araguás, Ernesto, Narváez, Javier, Camins-Fàbregas, Jordi, Ruiz-Román, Alberto, Loarce-Martos, Jesús, Holgado-Pérez, Susana, Flores-Rodríguez, V Miguel, Sivera, Francisca, Merino-Argumanez, Carolina, and Juan-Mas, Antonio

Published
2025
Full Text
View/download PDF

10. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*

Author

Blanco, Francisco J., Silva-Díaz, Maite, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2021
Full Text
View/download PDF

11. Prevalencia de artrosis sintomática en España: Estudio EPISER2016

Author

Blanco, Francisco J., Silva-Díaz, Maite, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2021
Full Text
View/download PDF

12. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register

Author

Ricardo Blanco, Miguel A González-Gay, Alejandro Muñoz, María Jesús García-Villanueva, Jesús T Sanchez-Costa, Paula Estrada, Cristina Valero Martínez, Patricia Moya Alvarado, Vanessa A Navarro Angeles, Carlos Galisteo Lencastre Da Veiga, Anne Riveros Frutos, Jose A Román Ivorra, Selena Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María García-Gonzalez, María Alcalde Villar, Antonio Juan Mas, and Clara Molina-Almela

Subjects
Medicine
Abstract

Objective The main study objective was to determine how giant cell arteritis (GCA) is diagnosed in our clinical practice and whether the EULAR recommendations have influenced the diagnostic procedures used.Methods ARTEritis of the Rheumatology Spanish Society -Sociedad Española de Reumatología (ARTESER) is a multicentre observational retrospective study conducted in 26 hospitals with support from the Spanish Society of Rheumatology. All patients diagnosed with GCA between 1 June 2013 and 29 March 2019 were included. The gold standard for the diagnosis of GCA was the judgement of the physician in charge, according to clinical criteria, supported by data available from laboratory tests, imaging studies (ultrasound, positron emission tomography (PET) and MRI/CT angiography) and temporal artery biopsy (TAB) when available.Results We included 1675 patients with GCA (mean age±SD (76.9±8.1) years, 1178 women (70.3%)). Of these, 776 patients had a positive TAB (46.3%), 503 (30.0%) positive ultrasound, 245 positive PET (14.6%) and 64 positive MRI/CT angiography (3.8%). These percentages changed substantially over the study. From 2013 to 2019, the use of ultrasound in diagnosis grew from 25.8% to 52.9% and PET from 12.3% to 19.6%, while use of TAB decreased from 50.3% to 33.3%.Conclusions Biopsy was the most widely used diagnostic test for confirming GCA, but use of imaging as a diagnostic tool has grown in recent years. Following publication of the 2018 EULAR recommendations, ultrasound has displaced biopsy as the first-line diagnostic test; TAB was performed in a third and PET in a fifth of cases.

Published
2022
Full Text
View/download PDF

13. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Author

Antonio Julià, María López-Lasanta, Francisco Blanco, Antonio Gómez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz García Vivar, Jordi Monfort, Simón Sánchez-Fernández, Isidoro González, Mercedes Alperi, Raúl Castellanos-Moreira, Antonio Fernández-Nebro, César Díaz-Torné, Núria Palau, Raquel Lastra, Jordi Lladós, Raimon Sanmartí, and Sara Marsal

Subjects
Rheumatoid arthritis, Treatment response, Anti-TNF therapy, Autoantibodies, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.

Published
2021
Full Text
View/download PDF

14. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Author

Antonio Julià, Antonio Gómez, María López-Lasanta, Francisco Blanco, Alba Erra, Antonio Fernández-Nebro, Antonio Juan Mas, Carolina Pérez-García, Ma Luz García Vivar, Simón Sánchez-Fernández, Mercedes Alperi-López, Raimon Sanmartí, Ana María Ortiz, Carlos Marras Fernandez-Cid, César Díaz-Torné, Estefania Moreno, Tianlu Li, Sergio H. Martínez-Mateu, Devin M. Absher, Richard M. Myers, Jesús Tornero Molina, and Sara Marsal

Subjects
Rheumatoid arthritis, TNF inhibitors, Treatment response, Epigenetics, DNA methylation, Medicine, Medicine (General), R5-920
Abstract

Summary: Background: Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease of the joints that has been associated with variation in the peripheral blood methylome. In this study, we aim to identify epigenetic variation that is associated with the response to tumor necrosis factor inhibitor (TNFi) therapy. Methods: Peripheral blood genome-wide DNA methylation profiles were analyzed in a discovery cohort of 62 RA patients at baseline and at week 12 of TNFi therapy. DNA methylation of individual CpG sites and enrichment of biological pathways were evaluated for their association with drug response. Using a novel cell deconvolution approach, altered DNA methylation associated with TNFi response was also tested in the six main immune cell types in blood. Validation of the results was performed in an independent longitudinal cohort of 60 RA patients. Findings: Treatment with TNFi was associated with significant longitudinal peripheral blood methylation changes in biological pathways related to RA (FDR

Published
2022
Full Text
View/download PDF

15. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

Author

Torrente-Segarra, Vicenç, Salman-Monte, Tarek C., Rúa-Figueroa, Íñigo, del Campo, Víctor, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Olivé-Marqués, Alejandro, Mouriño-Rodríguez, Coral, Horcada, Loreto, Bohórquez, Cristina, Montilla, Carlos, Salgado, Eva, Díez-Álvarez, Elvira, Blanco, Ricardo, Andreu, José Luis, Fernández-Berrizbeitia, Olaia, Expósito, Lorena, Gantes, Marian, Hernández-Cruz, Blanca, Pecondón-Español, Ángela, Lozano-Rivas, Nuria, Bonilla, Gema, Lois Iglesias, Ana, Rubio-Muñoz, Paula, Ovalles, Juan, Tomero, Eva, Boteanu, Alina, Narvaez, Javier, Freire, Mercedes, Vela, Paloma, Quevedo-Vila, Víctor, Juan Mas, Antonio, Muñoz-Fernández, Santiago, Raya, Enrique, Moreno, Mireia, Velloso-Feijoo, ML, Soler, Gregorio, Vázquez-Rodríguez, Tomás Ramón, and Pego-Reigosa, José M.

Published
2020
Full Text
View/download PDF

16. Valoración del riesgo de fractura en población general en España mediante el algoritmo FRAX®: Estudio EPISER2016

Author

Silva-Fernández, Lucía, Sivera, Francisca, Quilis Martí, Neus, Blanco, Francisco J., Pérez Ruiz, Fernando, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Val del Amo, Natividad, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Gandía Martínez, Myriam, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Gómez-Vaquero, Carmen, Fábregas-Canales, Dolores, Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2020
Full Text
View/download PDF

20. Prevalence of Rheumatic Diseases in Adult Population in Spain (EPISER 2016 Study): Aims and Methodology

Author

Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Silva-Fernández, Lucía, Sivera, Francisca, Blanco, Francisco J., Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis Martí, Neus, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Amo, Natividad del Val, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Ruiz Tudela, María del Mar, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Díaz-González, Federico, and Bustabad, Sagrario

Published
2019
Full Text
View/download PDF

21. Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodología

Author

Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Silva-Fernández, Lucía, Sivera, Francisca, Blanco, Francisco J., Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis Martí, Neus, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Amo, Natividad del Val, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Ruiz Tudela, María del Mar, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Díaz-González, Federico, and Bustabad, Sagrario

Published
2019
Full Text
View/download PDF

23. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study.

Author

López-Medina, Clementina, Calvo-Gutiérrez, Jerusalem, Ábalos-Aguilera, M. Carmen, Cepas, Francisco, Plasencia-Rodríguez, Chamaida, Martínez-Feito, Ana, Balsa, Alejandro, Faré-García, Regina, Juan-Mas, Antoni, Ruiz-Esquide, Virginia, Sainz, Luis, Díaz-Torné, César, Javier Godoy-Navarrete, Francisco, Añón-Oñate, Isabel, Mena-Vázquez, Natalia, Manrique-Arija, Sara, Marina Soledad Moreno-García, Ortega-Castro, Rafaela, and Escudero-Contreras, Alejandro

Published
2024
Full Text
View/download PDF

25. Evaluation of the impact of nursing clinics in the rheumatology services

Author

Muñoz-Fernández, Santiago, Aguilar, Ma Dolores, Rodríguez, Amparo, Almodóvar, Raquel, Cano-García, Laura, Gracia, Luís Antonio, Román-Ivorra, José A., Rodríguez, J. Ramón, Navío, Teresa, Lázaro, Pablo, Alegre-López, Javier, Alegre-Sancho, Juan José, Belzunegui-Otano, Joaquín, Bermúdez Torrente, Alberto, Bustabad Reyes, Sagrario, Calvo-Catalá, Javier, Campos-Esteban, José, Carbonell Jorda, Amelia, Castro-Oreiro, Sonia, Cerdá-Gabaroi, Dacia, Collantes-Estevez, Eduardo, Corteguera Coro, Montserrat, Espadaler Poch, Lluis, Fernández-Carballido, Cristina, Fernández Nebro, Antonio, Flores Torre, Manuel, García de Vicuña, Rosario, García Vivar, Mª Luz, Gómez España, Mª Victoria, Fortea, Sandra, Juan Mas, Antonio, Larrosa-Padró, Marta, Manero Ruiz, Javier, Martín-Mola, Emilio, Mateo-Bernardo, Isabel, Moya-Alvarado, Patricia, Noguera-Pons, José Raúl, Nolla Soléc, Joan Miquel, Peiró Callizo, Enriqueta, Pérez-Sandoval, Trinidad, Pina Pérez, Francisca, Del Pino Montes, Javier, Polo-Ostariz, Miguel Ángel, Rodríguez Heredia, José Manuel, Rodríguez Lozano, Carlos, Alcañiz, Cristina Patricia, Romero-Yuste, Susana, Roselló-Pardo, Rosa, Rusiñol-Badals, María, Sampedro-Álvarez, Juana, Sánchez-Atrio, Ana Isabel, Sánchez-Andrade Fernández, Amalia, Torre Alonso, Juan Carlos, Valero-Expósito, Marta, Vázquez-Díaz, Mónica, Veiga-Cabello, Raúl, and SCORE Working Group

Published
2016
Full Text
View/download PDF

26. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study—results at 5 years of follow-up.

Author

Martín-Martínez, María A, Castañeda, Santos, Sánchez-Alonso, Fernando, García-Gómez, Carmen, González-Juanatey, Carlos, Sánchez-Costa, Jesús T, Belmonte-López, María A, Tornero-Molina, Jesús, Santos-Rey, José, González, Carmen O Sánchez, Quesada, Estefanía, Moreno-Gil, María P, Cobo-Ibáñez, Tatiana, Pinto-Tasnde, José A, Babío-Herráez, Jesús, Bonilla, Gema, Juan-Mas, Antonio, Manero-Ruiz, Francisco J, Romera-Baurés, Montserrat, and Bachiller-Corral, Javier

Subjects
CARDIOVASCULAR disease related mortality, CARDIOVASCULAR diseases risk factors, PSORIATIC arthritis, CONFIDENCE intervals, ANKYLOSING spondylitis, CARDIOVASCULAR diseases, DISEASE incidence, RISK assessment, DESCRIPTIVE statistics, PUBLIC hospitals, RHEUMATOID arthritis, RHEUMATISM, LONGITUDINAL method, POISSON distribution, PROPORTIONAL hazards models
Abstract

Objectives To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up. Methods This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n  = 775), AS (n  = 738) and PsA (n  = 721), and individuals without CIRD (n  = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain. Descriptive analyses were performed for the CV mortality at 5 years. The Systematic COronary Risk Evaluation (SCORE) function at 5 years was calculated to determine the expected risk of CV mortality. Poisson models were used to estimate the incidence rates of the first CVE. Hazard ratios of the risk factors involved in the development of the first CVE were evaluated using the Weibull proportional hazard model. Results Overall, 2382 subjects completed the follow-up visit at 5 years. Fifteen patients died due to CVE. CV deaths observed in the CIRD cohort were lower than that predicted by SCORE risk charts. The highest incidence rate of CVE [7.39 cases per 1000 person-years (95% CI 4.63, 11.18)] was found in PsA patients. However, after adjusting for age, sex and CV risk factors, AS was the inflammatory disease more commonly associated with CVE at 5 years [hazard ratio 4.60 (P  =0.02)], compared with those without CIRD. Conclusions Cardiovascular mortality in patients with CIRD at 5 years of follow-up is lower than estimated. Patients with AS have a higher risk of developing a first CVE after 5 years of follow-up. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.

Author

Fernández-Díaz, Carlos, Castañeda, Santos, Melero-González, Rafael B, Ortiz-Sanjuán, Francisco, Juan-Mas, Antonio, Carrasco-Cubero, Carmen, Casafont-Solé, Ivette, Olivé, Alejandro, Rodríguez-Muguruza, Samantha, Almodóvar-González, Raquel, Castellanos-Moreira, Raul, Rodríguez-García, Sebastian C, Aguilera-Cros, Clara, Villa, Ignacio, Ordóñez-Palau, Sergio, Raya-Alvarez, Erique, Morales-Garrido, Pilar, Ojeda-García, Clara, Moreno-Ramos, Manuel J, and Hernán, María Gema Bonilla

Subjects
RHEUMATOID arthritis diagnosis, INTERSTITIAL lung diseases, MEDICAL cooperation, RESEARCH, RHEUMATOID arthritis, STATISTICS, DATA analysis, TREATMENT effectiveness, DATA analysis software, ABATACEPT, DESCRIPTIVE statistics
Abstract

Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was an observational, multicentre study of RA-ILD patients treated with at least one dose of ABA. ILD was diagnosed by high-resolution CT (HRCT). We analysed the following variables at baseline (ABA initiation), 12 months and at the end of the follow-up: Modified Medical Research Council (MMRC) scale (1-point change), forced vital capacity (FVC) or diffusion lung capacity for carbon monoxide (DLCO) (improvement or worsening ≥10%), HRCT, DAS on 28 joints evaluated using the ESR (DAS28ESR) and CS-sparing effect. Results We studied 263 RA-ILD patients [150 women/113 men; mean (s. d.) age 64.6 (10) years]. At baseline, they had a median duration of ILD of 1 (interquartile range 0.25–3.44) years, moderate or severe degree of dyspnoea (MMRC grade 2, 3 or 4) (40.3%), FVC (% of the predicted) mean (s. d.) 85.9 (21.8)%, DLCO (% of the predicted) 65.7 (18.3) and DAS28ESR 4.5 (1.5). The ILD patterns were: usual interstitial pneumonia (UIP) (40.3%), non-specific interstitial pneumonia (NSIP) (31.9%) and others (27.8%). ABA was prescribed at standard dose, i.v. (25.5%) or s.c. (74.5%). After a median follow-up of 12 (6–36) months the following variables did not show worsening: dyspnoea (MMRC) (91.9%); FVC (87.7%); DLCO (90.6%); and chest HRCT (76.6%). A significant improvement of DAS28ESR from 4.5 (1.5) to 3.1 (1.3) at the end of follow-up (P  < 0.001) and a CS-sparing effect from a median 7.5 (5–10) to 5 (2.5–7.5) mg/day at the end of follow-up (P  < 0.001) was also observed. ABA was withdrawn in 62 (23.6%) patients due to adverse events (n  = 30), articular inefficacy (n  = 27), ILD worsening (n  = 3) and other causes (n  = 2). Conclusion ABA may be an effective and safe treatment for patients with RA-ILD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. Exposure Levels Associated With Na131I Thyroid Cancer Patients

Author

Michelle T. Domingo, James N. Dykes, Dave Yamauchi, George Lopatin, Juan Mas, Charles A. Pickering, and Lawrence E. Williams

Subjects
Male, medicine.medical_specialty, Correlation coefficient, Epidemiology, Health, Toxicology and Mutagenesis, Initial activity, Sodium Iodide, Gastroenterology, Body Mass Index, Iodine Radioisotopes, Correlation, Eating, Occupational Exposure, Internal medicine, medicine, Humans, PATIENT PHYSICAL, Ingestion, Family, Radiology, Nuclear Medicine and imaging, Thyroid Neoplasms, Radiometry, Thyroid cancer, business.industry, Environmental Exposure, medicine.disease, Confidence interval, Endocrinology, Female, business, Body mass index
Abstract

Initial radiation exposure levels X (0) at 1 m from the navel of thyroid cancer patients were measured for 165 individuals at the time of ingestion. Some 61 patients had previously signed informed consent so only those patients could be assayed with regard to body parameters. While the activity was in the stomach, resultant X (0) values were seen to be linearly correlated with the total (131)I activity (A) given orally. Yet large differences in X (0) were seen; e.g., at A = 7.4 GBq, variations of a factor of four were found between the largest and smallest exposure rates. Correlation analyses were performed between normalized rate X (0)A-1 and several patient physical parameters. These included age, sex, height, weight, and BMI (body mass index). Only weight and BMI had significant linear correlation (p < 0.05) with normalized exposure rate. In the former case, the correlation coefficient ρ (weight) was -0.296 (p = 0.02). Using BMI as the independent variable, ρ (BMI) was -0.386 (p = 0.0021). With further analysis of the BMI variation, 95% confidence intervals could be determined at various BMI levels. For example, at 28 kg m(-2), the normalized rate varied between 0.039 and 0.0446 μGy h(-1) MBq(-1)-approximately a ±6.5% variation on the mean value of 0.0419 μGy h(-1) MBq(-1) at this BMI. Given such clinical information, differences in normalized exposure rate can be reduced to values on the order of ±10% or less for BMI values over the clinically relevant interval 20 to 40 kg m(-2).

Published
2014
Full Text
View/download PDF

30. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database

Author

Avouac, Jerome, Walker, Ulrich, Tyndall, Alan, Kahan, André, Matucci Cerinic, Marco, Allanore, Yannick, Miniati, I., Müller, A., Iannone, F., Giacomelli, R., Distler, O., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Coelho, P., Cabane, J., Cutolo, M., Shoenfeld, Y., Rovensky, J., Riemekasten, G., Nicoara, I., Vlachoyiannopoulos, P., Caporali, R., Jiri, S., Inanc, M., Gorska, I. Zimmermann, Carreira, P., Novak, S., Czirjak, L., Ramos, F. Oliveira, Jendro, M., Chizzolini, C., Kucharz, E. J., Richter, J., Cozzi, F., Rozman, B., Mallia, C. M., Gabrielli, A., Farge, D., Kiener, H. P., Schöffel, D., Sticherling, M., Airo, P., Wollheim, F., Martinovic, D., Trotta, F., Hunzelmann, N., Jablonska, S., Reich, K., Bombardieri, S., Siakka, P., Pellerito, R., Bambara, L. M., Morovic Vergles, J., Denton, C., Hinrichs, R., Van Den Hoogen, F., Damjanov, N., Kötter, I., Ortiz, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Van Laar, J. M., Kaltwasser, J. P., Foeldvari, I., Juan Mas, A., Bajocchi, G., Wislowska, M., Pereira Da Silva, J. A., Jacobsen, S., Worm, M., Graniger, W., Kuhn, A., Stankovic, A., Cossutta, R., Majdan, M., Rajcevska, L. Damjanovska, Tikly, M., Nasonov, E. L., Steinbrink, K., Herrick, A., Müller Ladner, U., Dinc, A., Scorza, R., Sondergaard, K., Indiveri, F., Nielsen, H., Szekanecz, Z., Silver, R. M., Antivalle, M., Espinosa, I. B., García De La Pena Lefebvre, P., Midtvedt, O., Launay, D., Valesini, F., Tuvik, P., Ionescu, R. M., Del Papa, N., Pinto, S., Wigley, F., Mihai, C., Capranu, M. Sinziana, Sunderkötter, C., Jun, J. B., Derk, C., Alhasani, S., Distler, J. H., Ton, E., Soukup, T., Seibold, J., Zeni, S., Nash, P., Mouthon, L., De Keyser, F., Duruöz, M. T., Cantatore, F. P., Strauss, G., Von Mülhen, C. A., Pozzi, M. R., Eyerich, K., Szechinski, J., Keiserman, M., Houssiau, F. A., Rom Ivorra, J. A., Krummel Lorenz, B., Aringer, M., Westhovens, R., Bellisai, F., Mayer, M., Stoeckl, F., Üprus, M., Volpe, A., Buslau, M., Yavuz, S., Granel, B., Feijó, A. Valderílio, Del Galdo, F., Popa, S., Zenone, T., Machado, X. Ricardo, Pileckyte, M., Stebbings, S., Mathieu, A., Tulli, A., Tourinho, T., Souza, R., Acayaba De Toledo, R., Stamp, L., Solanki, K., Veale, D., Neto, J. Francisco Marques, Bagnato, G. F., Loyo, E., Toloza, S., Li, M., Mohamed, W. Ahmed Abdel Atty, Cobankara, V., Olas, J., Salsano, F., Oksel, F., Tanaseanu, C. M., Foti, R., Ancuta, C., Vonk, M., Caramashi, P., Beretta, L., Balbir, A., Shine, B., Chiàla, A., Simic, K. Pasalic, Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Hachulla, E., Furst, D. E., VALENTINI, Gabriele, Avouac, Jerome, Walker, Ulrich, Tyndall, Alan, Kahan, André, Matucci Cerinic, Marco, Allanore, Yannick, Miniati, I., Müller, A., Iannone, F., Giacomelli, R., Distler, O., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Coelho, P., Cabane, J., Cutolo, M., Shoenfeld, Y., Valentini, Gabriele, Rovensky, J., Riemekasten, G., Nicoara, I., Vlachoyiannopoulos, P., Caporali, R., Jiri, S., Inanc, M., Gorska, I. Zimmermann, Carreira, P., Novak, S., Czirjak, L., Ramos, F. Oliveira, Jendro, M., Chizzolini, C., Kucharz, E. J., Richter, J., Cozzi, F., Rozman, B., Mallia, C. M., Gabrielli, A., Farge, D., Kiener, H. P., Schöffel, D., Sticherling, M., Airo, P., Wollheim, F., Martinovic, D., Trotta, F., Hunzelmann, N., Jablonska, S., Reich, K., Bombardieri, S., Siakka, P., Pellerito, R., Bambara, L. M., Morovic Vergles, J., Denton, C., Hinrichs, R., Van Den Hoogen, F., Damjanov, N., Kötter, I., Ortiz, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Van Laar, J. M., Kaltwasser, J. P., Foeldvari, I., Juan Mas, A., Bajocchi, G., Wislowska, M., Pereira Da Silva, J. A., Jacobsen, S., Worm, M., Graniger, W., Kuhn, A., Stankovic, A., Cossutta, R., Majdan, M., Rajcevska, L. Damjanovska, Tikly, M., Nasonov, E. L., Steinbrink, K., Herrick, A., Müller Ladner, U., Dinc, A., Scorza, R., Sondergaard, K., Indiveri, F., Nielsen, H., Szekanecz, Z., Silver, R. M., Antivalle, M., Espinosa, I. B., García De La Pena Lefebvre, P., Midtvedt, O., Launay, D., Valesini, F., Tuvik, P., Ionescu, R. M., Del Papa, N., Pinto, S., Wigley, F., Mihai, C., Capranu, M. Sinziana, Sunderkötter, C., Jun, J. B., Derk, C., Alhasani, S., Distler, J. H., Ton, E., Soukup, T., Seibold, J., Zeni, S., Nash, P., Mouthon, L., De Keyser, F., Duruöz, M. T., Cantatore, F. P., Strauss, G., Von Mülhen, C. A., Pozzi, M. R., Eyerich, K., Szechinski, J., Keiserman, M., Houssiau, F. A., Rom Ivorra, J. A., Krummel Lorenz, B., Aringer, M., Westhovens, R., Bellisai, F., Mayer, M., Stoeckl, F., Üprus, M., Volpe, A., Buslau, M., Yavuz, S., Granel, B., Feijó, A. Valderílio, Del Galdo, F., Popa, S., Zenone, T., Machado, X. Ricardo, Pileckyte, M., Stebbings, S., Mathieu, A., Tulli, A., Tourinho, T., Souza, R., Acayaba De Toledo, R., Stamp, L., Solanki, K., Veale, D., Neto, J. Francisco Marque, Bagnato, G. F., Loyo, E., Toloza, S., Li, M., Mohamed, W. Ahmed Abdel Atty, Cobankara, V., Olas, J., Salsano, F., Oksel, F., Tanaseanu, C. M., Foti, R., Ancuta, C., Vonk, M., Caramashi, P., Beretta, L., Balbir, A., Shine, B., Chiàla, A., Simic, K. Pasalic, Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Hachulla, E., Furst, D. E., Chizzolini, Carlo, and Westhovens, Rene

Subjects
Male, Systemic disease, Databases, Factual, Cross-sectional study, Joint Diseases/etiology/pathology/physiopathology, Systemic inflammation, Joint involvement, Scleroderma, systemic sclrosis, systemic inflemmetion, joint involvement, Tendons, Systemic sclerosi, Scleroderma, Localized, 0302 clinical medicine, data base, Immunopathology, joint radiography, Immunology and Allergy, Joints/pathology, scleroderma, 030212 general & internal medicine, nuclear magnetic resonance imaging, Range of Motion, Articular, skin and connective tissue diseases, rheumatic disease, ddc:616, interstitial lung disease, Joint contracture, Clinical Trials as Topic, Synovitis, Inflammation/etiology/pathology/physiopathology, integumentary system, article, Tendons/pathology, Middle Aged, musculoskeletal system, cohort analysis, Connective tissue disease, priority journal, Joint, Synoviti, Systemic sclerosis, Female, medicine.symptom, Joint Diseases, Human, musculoskeletal diseases, Adult, medicine.medical_specialty, hand radiography, Immunology, Scleroderma, Localized/etiology/*pathology, Auto-immunity, transplantation and immunotherapy [N4i 4], 03 medical and health sciences, SYSTEMIC SCLEROSIS, JOINT INVOLVEMENT, SYNOVITIS, JOINT CONTRACTURE, TENDON FRICTION RUB, Tendon friction rub, Rheumatology, Internal medicine, medicine, Humans, Health care ethics [NCEBP 5], Tendon, Aged, 030203 arthritis & rheumatology, Cross-Sectional Studie, Inflammation, skin disease, Scleroderma, Systemic, business.industry, echography, medicine.disease, major clinical study, tenosynovitis, Synovitis/etiology/pathology, clinical feature, body regions, Cross-Sectional Studies, Evaluation of complex medical interventions [NCEBP 2], Scleroderma, Systemic/complications/pathology/physiopathology, Joints, disease duration, business, Joint Disease, disease activity
Abstract

Objective.To determine the prevalence of and independent factors associated with joint involvement in a large population of patients with systemic sclerosis (SSc).Methods.This study was cross-sectional, based on data collected on patients included in the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) registry. We queried this database to extract data regarding global evaluation of patients with SSc and the presence of any clinical articular involvement: synovitis (tender and swollen joints), tendon friction rubs (rubbing sensation detected as the tendon was moved), and joint contracture (stiffness of the joints that decreased their range of motion). Overall joint involvement was defined by the occurrence of synovitis and/or joint contracture and/or tendon friction rubs.Results.We recruited 7286 patients with SSc; their mean age was 56 ± 14 years, disease duration 10 ± 9 years, and 4210 (58%) had a limited cutaneous disease subset. Frequencies of synovitis, tendon friction rubs, and joint contractures were 16%, 11%, and 31%, respectively. Synovitis, tendon friction rubs, and joint contracture were more prevalent in patients with the diffuse cutaneous subset and were associated together and with severe vascular, muscular, renal, and interstitial lung involvement. Moreover, synovitis had the highest strength of association with elevated acute-phase reactants taken as the dependent variable.Conclusion.Our results highlight the striking level of articular involvement in SSc, as evaluated by systematic examination in a large cohort of patients with SSc. Our data also show that synovitis, joint contracture, and tendon friction rubs are associated with a more severe disease and with systemic inflammation.

Published
2010
Full Text
View/download PDF

31. Arthrose érosive des pieds. Deux observations

Author

Antonio Juan Mas and Jaime Rotés-Querol

Subjects
Gynecology, medicine.medical_specialty, Rheumatology, business.industry, Arthropathy, Medicine, Articulation (phonetics), business, medicine.disease
Abstract

Resume L'arthrose erosive est une maladie essentiellement feminine consideree comme rare. Elle se localise habituellement aux articulations interphalangiennes des mains. Toutefois, elle a ete rapportee dans quelques cas a la hanche, a l'epaule ou au pied. Nous rapportons ici les observations d'un homme et d'une femme atteints d'une arthrose erosive des pieds.

Published
2007
Full Text
View/download PDF

32. IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Author

González-Moreno, Juan, García-Gasalla, Mercedes, Losada-López, Inés, Cifuentes Luna, Carmen, Mir Viladrich, Isabel, Fernández-Baca, Victoria, Serrano, Araceli, Juan Mas, Antonio, Riera-Oliver, Joan, and Payeras Cifre, Antoni

Subjects
TUBERCULOSIS, AUTOIMMUNE diseases, IMMUNOSUPPRESSION, GLUCOCORTICOIDS, CHRONIC diseases
Abstract

Diagnosis of latent tuberculosis infection in patients with immune-mediated inflammatory chronic diseases (IMIDs) can be challenged as diagnostic test reliability could be impaired by immunosuppression. We retrospectively analyzed the Quantiferon Gold-Test in-Tube (QFT-G-IT) results of all patients with IMIDs seen at the Department of Internal Medicine of Son Llàtzer Hospital, Palma de Mallorca (Spain), looking for the factors related to QFT-G-IT indeterminate results. During the study period (2008-2015), 520 patients met the inclusion criteria. Factors associated with indeterminate QFT-G-IT results in a univariate analysis were inflammatory bowel disease, disease activity, lymphopenia, and medium-to-high doses of corticosteroids. In a subsequent multivariate analysis, only lymphopenia (defined as < 1500 cells) was associated with indeterminate QFT-G-IT results. Lymphocyte count was the only factor independently associated with an increased number of indeterminate QFT-G-IT results in patients with different autoimmune diseases. Others factors such as the use of medium-to-high doses of corticosteroids should be considered before testing with QFT-G-IT. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

33. Diffuse idiopathic skeletal hyperostosis in a young woman treated with isotretinoin.

Author

Ibáñez Barceló, Monica, Estremera Rodrigo, Ana, Ros Vilamajó, Inmaculada, and Juan Mas, Antonio

Subjects
YOUNG women, ISOTRETINOIN, EXOSTOSIS, CERVICAL vertebrae
Abstract

Copyright of Reumatología Clínica is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

34. Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy.

Author

Comín-Colet, J., Sánchez-Corral, M., Alegre-Sancho, J., Valverde, J., López-Gómez, D., Sabaté, X., Juan-Mas, A., and Esplugas, E.

Subjects
HEART block, SYSTEMIC lupus erythematosus, ANTIMALARIALS
Abstract

Complete heart block (CHB) is a rare complication of systemic lupus erythematosus (SLE), mainly seen during an acute flare-up of the disease or after high-dose long-term treatment with antimalarial drugs, although anti-Ro and anti-RNP antibodies have also been implied by some authors. A 40-y-old woman developed CHB in the context of an acute flare-up of SLE, first diagnosed three years ago, having recently commenced hydroxychloroquine (HCQ) treatment. Anti-Ro and anti-RNP antibodies were also positive. No features of myocarditis were found. A temporary pacemaker was required and complete resolution was achieved on steroid therapy with withdrawal of antimalarial therapy. The characteristics of previous cases are well publicised and discussion focuses on the possible aetiology and pathogenesis of the present case. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

36. MENSAJES DE VUELTA.

Author

Garijo, Máximo Gómez, Urquiza, David, Souvirón, Beltrán, Ormaza, Pilar, Villaseñor, Juan Mas, and Porto, Javier Tourón

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results